The Obama Administration has unveiled its budget 2012 budget and it contains both good and bad news for drugmakers. In addition to $1 billion boost to the National Institutes of Health budget, the administration wants to cut biologic drug exclusivity down to seven years, instead of the proposed 12. Branded drugmakers are sure to balk at the proposal. Supporters of the 12-year period argue that the high cost of development should entitle drugmakers to a long exclusivity period recoup their costs, while generic drugmakers are anxious for the opportunity to make their own versions of blockbuster biologics. Report | Report